Last reviewed · How we verify
Selexipag for intravenous use
At a glance
| Generic name | Selexipag for intravenous use |
|---|---|
| Also known as | ACT-293987 |
| Sponsor | Actelion |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension (PHASE3)
- Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects (PHASE1)
- Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selexipag for intravenous use CI brief — competitive landscape report
- Selexipag for intravenous use updates RSS · CI watch RSS
- Actelion portfolio CI